v3.26.3
Events after the reporting date (Details)
€ / shares in Units, € in Thousands, $ in Millions
6 Months Ended
Aug. 18, 2026
EUR (€)
€ / shares
shares
Jun. 30, 2026
EUR (€)
Jun. 30, 2025
EUR (€)
Aug. 10, 2026
USD ($)
Disclosure of non-adjusting events after reporting period [line items]        
Net Capital Increase | €   € 0 € 14,932  
Share capital        
Disclosure of non-adjusting events after reporting period [line items]        
Net Capital Increase | €   € 10 € 417  
Strategic partnership with Swedish Orphan Biovitrum AB        
Disclosure of non-adjusting events after reporting period [line items]        
Upfront payment, commitment | $       $ 75
Strategic partnership with Swedish Orphan Biovitrum AB | Maximum        
Disclosure of non-adjusting events after reporting period [line items]        
Nearterm development milestone payments eligible | $       40
Regulatory and commercial milestone payments eligible | $       $ 465
Capital increase        
Disclosure of non-adjusting events after reporting period [line items]        
Total number of shares issued (in shares) | shares 17,647,059      
Par value per share (in EUR per share) | € / shares € 1.70      
Capital increase | Share capital        
Disclosure of non-adjusting events after reporting period [line items]        
Net Capital Increase | € € 30,000